Galychpharm PJSC (UKEX:GFARM) Equity-to-Asset: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

UKEX:GFARM Galychpharm PJSC UKEX:GFARM
14 GF Score
Price ₴100.00
! 1 Warning Sign
View Full Analysis

What is Galychpharm PJSC Equity-to-Asset?

Galychpharm PJSC UKEX:GFARM 14 Equity-to-Asset is 0.00 as of . 20. GuruFocus rates UKEX:GFARM with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Galychpharm PJSC's Total Stockholders Equity for the quarter that ended in . 20 was ₴0.00 Mil. Galychpharm PJSC's Total Assets for the quarter that ended in . 20 was ₴0.00 Mil.

The historical rank and industry rank for Galychpharm PJSC's Equity-to-Asset or its related term are showing as below:

UKEX:GFARM's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.6
* Ranked among companies with meaningful Equity-to-Asset only.

Galychpharm PJSC  (UKEX:GFARM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Galychpharm PJSC Equity-to-Asset Related Terms

Galychpharm PJSC Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Galychpharm PJSC's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galychpharm PJSC Equity-to-Asset Chart

Galychpharm PJSC Annual Data
Trend
Equity-to-Asset

Galychpharm PJSC Semi-Annual Data
Equity-to-Asset

UKEX:GFARM vs HSTC, STLT, NTRR: Equity-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Galychpharm PJSC's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galychpharm PJSC Equity-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galychpharm PJSC's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Galychpharm PJSC's Equity-to-Asset falls into.


UKEX:GFARM
14GF Score
Galychpharm PJSC UKEX:GFARM
Equity-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galychpharm PJSC Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Galychpharm PJSC's Equity to Asset Ratio for the fiscal year that ended in . 20 is calculated as

Equity to Asset (A: . 20 )=Total Stockholders Equity/Total Assets
=/
=

Galychpharm PJSC's Equity to Asset Ratio for the quarter that ended in . 20 is calculated as

Equity to Asset (Q: . 20 )=Total Stockholders Equity/Total Assets
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of 0.00 mean?
Galychpharm PJSC (UKEX:GFARM) has a Equity-to-Asset of 0.00 as of . 20. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Galychpharm PJSC and its competitors.
Is Galychpharm PJSC's Equity-to-Asset too high?
Galychpharm PJSC's current Equity-to-Asset is 0.00. Overall, Galychpharm PJSC has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galychpharm PJSC's Equity-to-Asset compare to HSTC and STLT?
Galychpharm PJSC's Equity-to-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Galychpharm PJSC and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galychpharm PJSC's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galychpharm PJSC stock overvalued right now?
Galychpharm PJSC (UKEX:GFARM) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. Galychpharm PJSC's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Galychpharm PJSC (UKEX:GFARM), the current Equity-to-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galychpharm PJSC Business Description

Address 6/8 Opryshkivska Street, Lviv, UKR, 79024
Galychpharm PJSC is engaged in the production and sale of drugs and other medicines. It offers phytochemical substances, crude drugs, injection ampoules, tablets, solutions, extracts, and syrups.
14GF Score

Get the complete analysis for UKEX:GFARM

Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₴100.00
Price